Estrogen and soy isoflavonoids decrease sensitivity of medulloblastoma and central nervous system primitive...

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• Medulloblastoma (MB) growth and migration are stimulated by 17β-estradiol (E2).
• Estrogen receptor beta (ERβ) and insulin-like growth factor 1 signaling mediate E2's effects by inhibiting apoptosis.
• Previous studies indicated E2 stimulates MB growth, but its effect on chemotherapy sensitivity was unknown.

Purpose of the Study:

• To determine if estrogens decrease medulloblastoma cell sensitivity to standard chemotherapeutic drugs.
• To investigate the role of estrogen receptors (ERs) in mediating these effects.
• To evaluate the impact of soy-derived phytoestrogens on medulloblastoma chemosensitivity.

Main Methods:

• In vitro cell viability and clonogenic survival assays were used.
• Concentration-response analyses assessed the effects of estradiol on chemotherapy drug cytotoxicity.
• Experiments involved ER antagonists, selective ER modulators, and ER-selective agonists/antagonists.

Main Results:

• Estradiol increased resistance to cisplatin in D283 Med cells by twofold.
• Estradiol decreased chemosensitivity to cisplatin, lomustine, and vincristine in D283 Med cells.
• ERβ agonists and soy phytoestrogens also reduced cisplatin sensitivity, while antiestrogens blocked estradiol's protective effects.

Conclusions:

• Estradiol and environmental estrogens reduce MB cell sensitivity to chemotherapy via ERβ.
• Inhibition of ER activity can block these protective effects, suggesting antiestrogen therapies.
• Reduced exposure to environmental estrogens may improve chemotherapy response in MB patients.